Journal
JOURNAL OF CROHNS & COLITIS
Volume 15, Issue 5, Pages 860-863Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjaa243
Keywords
Inflammatory bowel disease; Crohn's disease; ulcerative colitis; coronavirus disease 2019; IBD therapy
Categories
Funding
- Helmsley Charitable Trust [2003-04445]
- National Center for Advancing Translational Sciences [UL1TR002489]
- Pfizer
- Takeda
- Janssen
- Abbvie
- Lilly
- Genentech
- Boehringer Ingelheim
- Bristol Myers Squibb
- Celtrion
- Arenapharm
- [T32DK007634]
- [K23KD111995-01A1]
Ask authors/readers for more resources
More than one third of IBD patients stopped medication due to COVID-19, with those diagnosed with ulcerative colitis or IBD-unspecified less likely to stop compared to Crohn's disease patients. Specific medications such as 5-aminosalicylic acid were more likely to be continued, while anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped. Other demographic and clinical characteristics did not impact prescription patterns.
Background: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. Methods: IBD medications that were stopped due to COVID-19 were recorded in the SECURE-IBD registry in addition to demographic and clinical data. We conducted descriptive analyses to understand characteristics associated with stopping IBD medications in response to active COVID-19 infection. Results: Of 1499 patients, IBD medications were stopped in 518 [34.6%] patients. On bivariate and multivariable analyses, a diagnosis of ulcerative colitis or IBD-unspecified was associated with a lower odds of stopping medication compared with Crohn's disease (adjusted odds ratio [aOR] 0.6, 95% confidence interval [CI] 0.48, 0.75). When evaluating specific medications, 5-aminosalicylic acid was more likely to be continued [p <0.001] whereas anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped [global p <0.001]. Other demographic and clinical characteristics did not affect prescription patterns. Conclusions: IBD medications other than immunomodulators were continued in the majority of IBD patients with COVID-19, in the international SECURE-IBD registry. Future studies are needed to understand the impact of stopping or continuing IBD medications on IBD- and COVID-19 related outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available